Mubasher: Hikma Pharmaceuticals inked exclusive licensing deals with global biopharmaceutical leader Celltrion to commercialize six biosimilar treatments across the MENA region.

The agreements will expand access to affordable biologics in oncology, immune, allergic, ophthalmology, and skeletal disorders, according to a press release.

Under the partnership, Hikma Pharmaceutical will hold exclusive MENA commercial rights, while Celltrion manages development, manufacturing, and supply.

The move strengthens Hikma’s position as a leading biosimilars provider in the MENA region.

It also supports the company’s biotech strategy to improve patient outcomes, reduce healthcare system burdens, and transform hospital treatment standards.

Mazen Darwazah, Hikma Pharmaceuticals’ Executive Vice Chairman and President at MENA, said: “These treatments have the potential to significantly improve quality of life for patients living with chronic, debilitating, or life-threatening conditions.”

“The addition of these biosimilars enhances Hikma’s ability to serve hospital channels with a comprehensive portfolio of injectable and biologics, reinforcing its ambition to become the top hospital player in the region,” Darwazah added.